chemotherapy-induced nausea and vomiting


Also found in: Dictionary, Thesaurus, Encyclopedia.

chemotherapy-induced nausea and vomiting (CINV)

nausea and vomiting occurring as a reaction to chemotherapeutic agents.

chemotherapy-induced emesis

An adverse effect of many chemotherapeutics, which is usually self-limited and rarely life-threatening.
 
Highly emetogenic
Cisplatin, carmustine, dacarbazine, dactinomycin, mechlorethamine (nitrogen mustard), streptozocin.
 
Moderately emetogenic
Azacitidine, arparginase, carboplatin, cyclophosphamide, doxorubicin, mitomycin.
 
Management
Dopamine (D2 high-dose metoclopramide), serotonin (5-HT3 receptor antagonists—e.g., ondansetron),

chemotherapy-induced nausea and vomiting

Vomiting that occurs after the administration of drugs used to treat cancer. Although its causes are complex, it appears to result from both direct irritation of the gastrointestinal tract by cytotoxic drugs, and the release of chemical mediators, such as 5-hydroxytryptamine (5-HT), from the gastrointestinal tract. 5-HT antagonists are among the most effective treatments. Dopaminergic effects in the central nervous system are also involved in chemotherapy-induced nausea and vomiting, and drugs that antagonize these effects, such as phenothiazines and other neuroleptics, can be used to treat the syndrome. Endocannabinoid drugs, corticosteroids (such as dexamethasone), antianxiety drugs (such as lorazepam) also have selected uses. Drugs that block receptors for neurokinins (such as aprepitant) are esp. effective in treating emesis that occurs more than 24 hours after chemotherapy.
References in periodicals archive ?
A study is proposed to investigate the effect of acupuncture on the control of chemotherapy-induced nausea and vomiting that is not controlled completely with modern pharmacological regimens.
Acupuncture as a complementary therapy in chemotherapy-induced nausea and vomiting
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study Ann Oncol.
TGA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
A Phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Eisai Oncology & Helsinn Group to Present New CINV Research at 2014 International Symposium on Supportive Care in Cancer
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-H[T.
Palonosetron (Aloxi): a second-generation 5-H[T.sub.3] receptor antagonist for chemotherapy-induced nausea and vomiting
3] receptor antagonist, palonosetron, designed to target two critical pathways thought to be associated with chemotherapy-induced nausea and vomiting (CINV).
Helsinn Group and Eisai Announce FDA Acceptance of New Drug Application for Investigational Compound Netupitant 300 mg + Palonosetron 0.50 mg (NEPA)
Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients.
Neurowave Medical Technologies[TM] Launches Nometex[TM] -- A Unique Neuromodulation Device to Treat Chemotherapy-Induced Nausea and Vomiting
This is the first approval of a product for acute chemotherapy-induced nausea and vomiting (CINV) prevention in patients aged 1 month to 6 months.
FDA Approves ALOXI (palonosetron HCl) to Prevent Nausea and Vomiting due to Chemotherapy in Children as Young as 1 Month
based in Phoenix, Arizona, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of innovative products that address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders and also drug candidates for the treatment of various cancers and other diseases.
Insys Therapeutics, Inc. Announces Conference Call and Corporate Update
Charleston's product pipeline currently addresses Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV).
Charleston Laboratories, Inc. Announces Publication of Abstract for CL-108 Phase 3 Study at APS 2014
The vast majority of patients undergoing multiday-high dose chemotherapy and autologous stem cell transplantation still experience major acute and delayed chemotherapy-induced nausea and vomiting (CINV), showing how emesis control in the ASCT setting remains sub-optimal", said Dr.
Palonosetron Effectively Prevents Emesis and Nausea Induced by High Dose Chemotherapy in Patients Undergoing Autologous Stem Cell Transplantation
These actions have been taken to maximize the probability of approval by the FDA of APF530, its lead product candidate for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting.
A.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review Process
About Chemotherapy-induced Nausea and Vomiting (CINV) Chemotherapy-induced nausea and vomiting is among the most common side effects following therapy in patients with cancer.
Helsinn Group And Eisai Announce FDA Acceptance Of New Drug Application For Investigational Compound Netupitant 300 mg + Palonosetron 0.50 mg (NEPA)
Medical browser ?
Full browser ?